Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Brazil government has not asked U.S. for vaccines despite Mexico, Canada deal

Published 03/19/2021, 04:41 PM
Updated 03/19/2021, 07:20 PM
© Reuters. FILE PHOTO: Oxford/AstraZeneca's COVID-19 vaccine at a vaccination centre in Antwerp

By Gabriel Stargardter

RIO DE JANEIRO (Reuters) - Brazil's government has not yet asked the United States for spare COVID-19 vaccines, according to two people with knowledge of the matter, despite Washington agreeing this week to send 4 million doses of AstraZeneca (NASDAQ:AZN) shots to Mexico and Canada.

The country's Senate leader says he has requested U.S. help.

Brazil's coronavirus death toll, nearly 300,000, is second only to the United States, and its health system is buckling under a record surge in cases. President Jair Bolsonaro, who has questioned the "rush" for vaccines, is under growing pressure to get a grip on an outbreak he once dubbed a "little flu."

He has been criticized for a slow and patchy immunization program, which has led to a lack of vaccine supplies in Latin America's biggest country. Earlier this month, his government asked the Chinese embassy to help secure 30 million doses from China to ensure its vaccine program does not grind to a halt.

Despite the United States agreeing this week to loan shots to Mexico and Canada, the Bolsonaro government has not yet asked Washington for vaccine supplies, said the two sources, who asked not to be named due to political sensitivities.

Neither the Brazilian president's office nor the foreign ministry replied immediately to requests for comment. The U.S. State Department also did not respond immediately to questions.

U.S. President Joe Biden has come under pressure from countries around the world to share shots, particularly its stock of AstraZeneca vaccines, which are authorized for use elsewhere but not in the United States.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The president of the Brazilian Senate, Rodrigo Pacheco, said he wrote to Vice President Kamala Harris asking the U.S. government to allow Brazil to buy surplus vaccines. That, he said on Twitter, would help boost vaccination of Brazilians.

The AstraZeneca vaccine, which is the centerpiece of the Brazilian federal government's vaccine plan, has full regulatory approval in Brazil, meaning it could likely be used immediately.

This week, Bolsonaro's political nemesis, former President Luiz Inacio Lula da Silva, used a high-profile CNN interview to ask the U.S. government to share its vaccine stock with Brazil.

Lula's comments - coming shortly after his graft convictions were annulled, allowing him to run in next year's presidential election - pose a challenge to Bolsonaro, as any subsequent request could let his rival score political points.

Bolsonaro's relationship with Biden also got off to a rocky start after he waited nearly a month and a half to recognize the results of the U.S. election last year. Bolsonaro enjoyed much warmer relations with Donald Trump, Biden's predecessor and a political role model for the Brazilian president.

Almost eight out of 10 Brazilians think the pandemic is out of control in their country and more than half are "very afraid" they will get infected with coronavirus, a new Datafolha poll said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.